Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eloxx Pharmaceuticals Inc (NQ: ELOX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eloxx Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Why Eloxx Pharmaceuticals (ELOX) Stock Is Soaring Tuesday
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) shares are rocketing higher on Tuesday after Oppenheimer raised its price target from $50 to $55. 
Via Benzinga
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Plans To Take ELX-02 Into Pivotal Trial For Alport Syndrome
Via Benzinga
Recap: Eloxx Pharmaceuticals Q1 Earnings
Via Benzinga
Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress
From Eloxx Pharmaceuticals
Via GlobeNewswire
Final Data Report: Eloxx Touts Improved Lung Function For Cystic Fibrosis Candidate
Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) announced the final data assessment from the Phase 2 trial of ELX-02, the company's lead invest 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study 
From Eloxx Pharmaceuticals
Via GlobeNewswire
Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study
From Eloxx Pharmaceuticals
Via GlobeNewswire
Gold Down 1.5%; Baidu Earnings Top Estimates
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones dropping over 250 points on Tuesday. The Dow traded down 0.81% to 33,079.77 while the NASDAQ rose 0.11% to 12,378.50. The... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Edges Higher; Home Depot Posts Downbeat Sales
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning higher on Tuesday. The Dow traded down 0.58% to 33,155.20 while the NASDAQ rose 0.24% to 12,394.69. The S&P 500, also... 
Via Benzinga
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering. 
Via Benzinga
Why Is Troika (TRKA) Stock Up 31% Today?
Troika Media (TRKA) stock is rising higher on Tuesday after the release of its earnings report for the first quarter of 2023. 
Via InvestorPlace
Why Is Tivic Health Systems (TIVC) Stock Down 28% Today?
Tivic Health Systems (TIVC) stock is sliding lower on Tuesday after the company released its earnings report for the first quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Eloxx Pharmaceuticals (ELOX) Stock Down 27% Today?
Eloxx Pharmaceuticals (ELOX) stock is falling hard on Tuesday after the company provided a weak earnings report for Q1 2023. 
Via InvestorPlace
Why VirTra Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Gainers VivoPower International PLC (NASDAQ: VVPR) shares surged 88.3% to $0.8701 in pre-market trading as the company reported a definitive distribution agreement to distribute EV fleet charging... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start off the day with a breakdown of all the biggest pre-market stock movers worth keeping an eye on Tuesday! 
Via InvestorPlace
Tesla, C3.ai, Rumble, Eloxx, Nu: Why These 5 Stocks Are Drawing Investor Attention Today
Via Benzinga
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
From Eloxx Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
From Eloxx Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Stocks Choppy Amid Renewed Recession Buzz
The Dow Jones Industrial Average is flat midday but has brushed off steep premarket losses, as investors weigh looming recession concerns. 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.